Abstract
Many European groups have recently described that mutations at exon-12 of the nucleophosmin (NPM1) gene are the most frequent genetic lesion in patients with acute myeloid leukemia (AML), especially in the presence of a normal karyotype. This study explored the prevalence and clinical profile of NPM1 mutations in a cohort of 156 Chinese adults with AML. NPM1 exon-12 mutations were detected using direct sequencing or fragment analysis of genomic DNA polymerase chain reaction products. NPM1 mutations were present in 28.2% of the overall population, including 1/1 (100%) of M0, 11/27 (40.7%) of M1, 11/46 (23.9%) of M2,0/29 (0%) of M3,2/9 (22.2%) of M4,18/39 (46.2%) of M5, and 1/5 (20.0%) of M6. NPM1 gene mutations were more prevalent in patients with a normal karyotype (37 of 90; 41.1%) when compared with patients with karyotypic abnormalities (7 of 66; 10.6%;P <.001). Sequence analysis of 25 NPM1-mutated cases revealed known mutations (type A, D, NM, and PM) as well as one novel sequence variation (here named as type S). All mutational types were heterozygous and showed a 4 bp insertion. NPM1 mutations were significantly associated with old age (P <.05), high peripheral white blood cell count (P <.05), and the subtypes of French-American-British categories M1/M5, but negatively associated with expression of CD34 (P <.05) and CD117 (P <.05). Thus, this study provides the methods of NPM1 exon-12 mutations detection and related clinical data of NPM1 mutated cases in a Chinese population.
Similar content being viewed by others
References
Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.N Engl J Med. 2005;352:254–266.
Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.Cell. 2000;103:127–140.
Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.Blood. 2005;106:3733–3739.
Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).Blood. 2006;107:4011–4020.
Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.Blood. 2005;106:2854–2861.
Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.Cancer Res. 2006; 66:3310–3316.
Zhang Y, Zhang M, Yang L, Xiao Z. NPM1 mutations in myelodys- plastic syndromes and acute myeloid leukemia with normal karyotype.Leuk Res. 2006; [Epub ahead of print].
Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.Leukemia. 2005;19:1760–1767.
Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.Blood. 2005;106:3740–3746.
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties.Blood. 1998;92:2322–2333.
Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species.Nat Med. 1997; 3:1337–1345.
Dohner K, Dohner H. Rush hour in AML: news on NPM traffic.Blood. 2006; 107:4200–4201.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yan, L., Chen, S., Liang, J. et al. Analysis of NPM1 Gene Mutations in Chinese Adults with Acute Myeloid Leukemia. Int J Hematol 86, 143–146 (2007). https://doi.org/10.1532/IJH97.A10620
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.A10620